AAPP Scientific Poster Session Abstracts

A Comparison of the Efficacy of Long-Acting Injectable vs. Oral Naltrexone During Acute-Phase and Maintenance Alcohol Cessation Adherence Long-Acting Injectable Substance-Use Disorders VA Naltrexone Alcohol Use Disorder AUD Cessation

A Pilot Study Assessing Client Understanding and Use of Fentanyl Test Strips for Harm Reduction Opioids Substance-Use Disorders Harm Reduction

A Qualitative Report of Fentanyl Exposure Among People Who Use Drugs in Austin, Texas Opioids Substance-Use Disorders Fentanyl People Who Use Drugs

A Structured Benefit-Risk Assessment to Evaluate a Combination of Olanzapine and Samidorphan for the Treatment of Schizophrenia and Bipolar I Disorder Antipsychotics OLZ/SAM Benefit Risk BRAT Framework

Access to Inclusive & Culturally Sensitive Mental Healthcare in Pharmacy Students & Residents Education/Stigma BIPOC Barriers Resources Mental Health

Acetylcholine as a Regulator of Dopamine Pathways: Rationale for Selective Muscarinic Agonists as Candidates for Antipsychotic Drug Development Antipsychotics Schizophrenia Muscarinic Xanomeline KarXT

Adjunctive Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial Antipsychotics Bipolar Disorder Lumateperone

Agitation Medication Treatment Practices in Obese Patients Admitted to Emergency Department Antipsychotics Benzodiazepine Acute Agitation Obesity Obese

ALTO-ED: Opioid Use Reduction Program in Two Public Health System Emergency Departments Opioids Substance-Use Disorders Transitions Of Care

An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every 6-Month and 3-month Long-Acting Injectable Formulations of Paliperidone Palmitate Antipsychotics Long-Acting Injectable

Analysis and Follow-up of a Long-Acting Injectable Standard Operating Procedure Implementation at a Veterans Affairs Medical Center Adherence Antipsychotics Long-Acting Injectable VA

Analysis of Psychiatric Care and Prescribing Patterns for Patients with PTSD Treatment in a Federally Qualified Health Center Antidepressants Antipsychotics Anxiolytics Post-Traumatic Stress Disorder/ PTSD Stimulants Substance-Use Disorders Mood Stabilizers FQHC Pharmacotherapy

Anticholinergic Burden Among Patients Admitted to the Hospital with a Psychiatric Diagnosis Antidepressants Antipsychotics Anxiolytics Geriatrics Adverse Drug Reaction Anticholinergic

Anticholinergic use and antipsychotic initiation in dementia: an evaluation of prescribing at a Veterans Affairs Medical Center Antipsychotics Geriatrics VA Anticholinergic

Antidepressant Prescribing Patterns in Transgender Individuals Diagnosed with Gender Dysphoria and Mood or Anxiety Disorders Antidepressants Antipsychotics Anxiolytics Gender Dysphoria Transgender Mental Health Mood And Anxiety-Related Disorders

Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Analysis of Positive and Negative Syndrome Scale Categorial Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study Antipsychotics Schizophrenia Muscarinic Xanomeline KarXT

Antipsychotic Quetiapine Induces Resistance To Multiple Antibiotics In Escherichia Coli Via Loss-of-Function Mutations In MarR Antipsychotics Antibiotic Resistance SGA Psychotropics Repositioning Quetiapine

Assessing the Impact of Mental Health First Aid (MHFA) Training on Health Profession Students’ Attitudes Towards Mental Health and Mental Health Literacy Education/Stigma Mental Health First Aid Interprofessional

Assessing the Mental Health of the Hispanic/Latinx Population in the Bay Area during COVID-19 Pandemic Education/Stigma COVID-19 Minorities Hispanic/Latinx

Assessing the Mental Health, Physical Health, and Well-being of Doctor of Pharmacy Students Education/Stigma Well-Being Physical Health Mental Health

Assessing the Need for Gender Diverse Care Education Amongst Practicing Community Pharmacists: Phase II Education/Stigma LGBTQ+

Assessing the Use of Valproic Acid, Carbamazepine, Paroxetine, and Topiramate in Women of Childbearing Age Antidepressants Education/Stigma Mood Stabilizers Womens Health Teratogenicity Female Veterans

Assessment of College Students’ Attitudes and Knowledge on Opioid Overdose and Naloxone Education and Evaluating the Effectiveness of a New Naloxone Distribution Program at the University of Southern California Education/Stigma Opioids Naloxone Harm Reduction Student Population

Assessment Of Naloxone Use In Individuals With Opioid Use Disorder Education/Stigma Opioids Sleep Disorder Stimulants Substance-Use Disorders Naloxone Access Harm Reduction

Assessment of Oral Overlap with Antipsychotic Long-Acting Injectables Initiated in an Inpatient Setting Adherence Antipsychotics Long-Acting Injectable Transitions Of Care VA

Assessment of the Continuation vs Discontinuation of Newly Initiated Antipsychotics for Delirium Treatment in Hospitalized Patients Antipsychotics Geriatrics Delirium

Association between SSRI and SNRI use and worsening of Parkinson’s Disease in a veteran population Antidepressants Post-Traumatic Stress Disorder/ PTSD VA Parkinson's Disease Movement Disorders SSRI SNRI

Association Between Substance Use Disorders (SUD) Severity and COVID-19 Vaccination Status and Beliefs Opioids Substance-Use Disorders

Barriers to Treatment with Psychiatric Medications among People Who Are Incarcerated Transitions Of Care Psychotropics Treatment Barriers Forensic

Buprenorphine/Naloxone Film And Naloxone Nasal Spray Pharmacy Deserts In Harris County, Texas And Philadelphia County, Pennsylvania Opioids Substance-Use Disorders

Calcitonin-Gene Related Peptide Monoclonal Antibodies as a Substitute For Botulinum Toxin in Chronic Migraine During the COVID-19 Pandemic at a Veterans Affairs Healthcare System Neurology VA Migraine Headache CGRP

Cataloguing the Impact of Psychiatric Pharmacists through Literature Psychiatric Pharmacist BCPP

Characteristics of Inpatients Prescribed Dopamine Receptor Blocking Agents Adherence Antipsychotics

Characterizing the Relationship Between Exposure to Long Acting Benzodiazepines and Barbiturates, Alcohol, and Death Anxiolytics Neurology Substance-Use Disorders Alcohol Use Disorder Alcohol Withdrawal Benzodiazepine Barbiturates

Clozapine-Induced Hyperhidrosis: A Case Report and Review of Treatment Strategies Antipsychotics Clozapine Hyperhidrosis Schizophrenia

Co-Administration of Intramuscular Olanzapine or Haloperidol With Parenteral Benzodiazepines in the Emergency Department Antipsychotics Anxiolytics Emergency Department Medication Safety

Comparison of Alpha Agonist versus Antagonist for Post Traumatic Stress Disorder (PTSD) Nightmares in Pediatric Patients Child And Adolescent Psychiatry Post-Traumatic Stress Disorder/ PTSD

Comparison of Aripiprazole Dosing in Mood Disorders When Co-prescribed with Interacting Medications Antipsychotics Drug Interactions Affective Disorder/mood Disorder

Comparison of Early Antipsychotic Metabolic Monitoring and the Development of Abnormal Hemoglobin A1c Antipsychotics VA Metabolic Monitoring

Comparison of Inpatient Psychiatric Medication Management in Gender Diverse Youth with Cisgender Peers Child And Adolescent Psychiatry Transitions Of Care Special Populations Transgender Gender

Comparison Of Patient Outcomes With Long-Acting Injectable Paliperidone Versus Oral Risperidone Antipsychotic Treatment In Early Psychosis Antipsychotics Long-Acting Injectable VA Early Psychosis

Comparison of Pharmacy Operations Across State Psychiatric Hospitals in the U.S. Clinical Services Technology Systems State Hospital Inpatient Psychiatry

Competence, Concerns, and Readiness Regarding Opioid Overdose Management: A National Cross-Sectional Survey of the U.S. General Public Education/Stigma Opioids Substance-Use Disorders

COVID-5150: Psychiatric Pharmacists Involvement in the COVID-19 Response at a County Psychiatric Inpatient Hospital COVID-19 Screenings Psychiatric Pharmacist Provider Inpatient Psychiatry

Describe and Evaluate the Role of a Clinical Psychiatric Pharmacist in a Gender Health Program. Education/Stigma Suicide Transgender Gender Health

Determining the Impact of High-Density Lipoprotein Cholesterol Levels and their Influence on Movement Disorders in Patients Taking Antipsychotics Antipsychotics Movement Disorders

Developing a Patient Experience Instrument for Patient Medication Education Groups Education/Stigma Medication Group Survey Multisite

Development of a Resource Referral Tool for a Community Pharmacy Suicide Prevention Gatekeeper Training Program Suicide VA Community Pharmacy Prevention

Development of an Ambulatory Alcohol Detoxification Clinic Substance-Use Disorders Transitions Of Care VA

Development of Attribute Statements for a Best Practice Model for Outpatient Psychiatric Pharmacy Practice Best Practice Outpatient Psychiatry

Did The More Stringent Prescription Drug Monitoring Program (PDMP) Requirement Change The Way Benzodiazepines Are Prescribed At A Large Veteran Affairs Health Care System? Anxiolytics Post-Traumatic Stress Disorder/ PTSD Benzodiazepine Prescription Drug Monitoring Program Controlled Substances

Does the addition of a Maintenance Mood Stabilizer to an Established Antipsychotic Treatment Reduce the Frequency of Agitated Episodes Requiring ‘As-needed’ Medications in Patients with Schizoaffective Disorder? Antipsychotics Mood Stabilizers Acute Agitation Schizoaffective Disorder

Dose Patterns for Long-Term Deutetrabenazine Treatment in Patients With Tardive Dyskinesia by Baseline Abnormal Involuntary Movement Scale Item 8 Score Neurology Tardive Dyskinesia VMAT2 Inhibitor Disease Severity Dose Titration

Dosing Patterns and Outcomes in Older Adult Patients Initiated on Long-acting Injectable Antipsychotics Adherence Antipsychotics Geriatrics Long-Acting Injectable

Effect of a Buprenorphine-based Opioid Withdrawal Protocol on Rates of AMA Discharge Opioids Substance-Use Disorders

Effect of a Mindfulness Intervention on Burnout of Pharmacists in a Safety Net Health Care System Education/Stigma Burnout Wellness Mindfulness

Effect of Pharmacist-Led Tobacco Cessation Efforts in Patients with Severe Mental Illness Prescribed Varenicline Adherence Antipsychotics Education/Stigma Long-Acting Injectable Substance-Use Disorders VA Smoking Cessation Severe Mental Illnes Varenicline

Effect of Pharmacogenomic Testing on Clinical Outcomes of Patients with Major Depressive Disorder Antidepressants Pharmacogenomics

Effects of Cannabidiol Products on In Vitro Metabolism of Clozapine Antipsychotics Cannabidiol Drug Interactions

Efficacy and Safety of a Long-Acting Subcutaneous Antipsychotic (LASCA) Agent (TV-46000) in Patients With Schizophrenia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study (RISE Study) Antipsychotics Long-Acting Injectable Schizophrenia

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the ASCEND Trial Antidepressants NMDA Major Depression Clinical Trial Investigational

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the GEMINI Trial Antidepressants NMDA Major Depression Clinical Trial Investigational

Efficacy and Safety of Intramuscular Olanzapine versus Intramuscular Haloperidol for Acute Agitation and Aggression at a Pediatric Hospital Antipsychotics Child And Adolescent Psychiatry Acute Agitation And Aggression

Efficacy of Combination Therapy Using Naltrexone with and without Acamprosate in the Management of Alcohol Use Disorder in Veterans Adherence Opioids Substance-Use Disorders VA Naltrexone Acamprosate AUD

Efficacy of Liraglutide in Comparison to Metformin for the Management of Antipsychotic-Induced Weight Gain Antipsychotics Adverse Drug Reaction

Efficacy of Lorazepam in The Treatment of Catatonia: A Case Report Adherence Antipsychotics Catatonia Anorexia

Elevated Clozapine Levels After Janssen SARS-CoV-2 Vaccination: A Case Report Antipsychotics COVID-19 Catatonia Benzodiazapene

Enhancing Psychiatric Care in the COVID Era through Pharmacy-Based Long-Acting Injectable Delivery Training Antipsychotics Education/Stigma Long-Acting Injectable Suicide COVID-19 Pharmacy

Establishing the Feasibility of Enhanced Myocarditis Monitoring During Clozapine Initiation Antipsychotics Therapeutic Drug Monitoring

Evaluating Clozapine Toxicity Following Covid-19 Vaccination Antipsychotics COVID-19

Evaluating the Association of Montelukast Use on Neuropsychiatric Outcomes in Patients Hospitalized for COVID-19 VA COVID-19

Evaluating the Effectiveness of Buprenorphine E-consults and the Impact on Opioid Use Disorder Treatment Services Opioids Substance-Use Disorders Transitions Of Care VA Buprenorphine/naloxone Opioid-Use Disorders

Evaluating the Impact of a Medication Access Program in Underserved Mental Health Patients Adherence Transitions Of Care

Evaluating the Impact of Involuntary Medication Orders on a Patient's Length of Stay at a State Forensic Psychiatric Hospital Antipsychotics Forensic Psychiatry Involuntary Medication Orders

Evaluating the Utility of a Required Didactic Mental Health First Aid Training Course Among First-year Pharmacy Students Education/Stigma Mental Health First Aid Didactic Training

Evaluation of a VA Medical Center’s Care Coordination Processes With Long-Acting Injectable Antipsychotics Adherence Antipsychotics Long-Acting Injectable Transitions Of Care VA Care Coordination

Evaluation of Agitation Events Treated with an ‘As-needed’ Medication in Patients Diagnosed with Schizophrenia and Schizoaffective Disorder Receiving Typical Versus Atypical Antipsychotics Antipsychotics Schizoaffective Disorder Schizophrenia Acute Agitation

Evaluation of Anticholinergic Medication Burden in Patients with Schizophrenia or Schizoaffective Disorder Antidepressants Antipsychotics Anticholinergic Burden

Evaluation of Buprenorphine/Naloxone Micro-Induction Protocol and Treatment Retention in Veterans Positive for Fentanyl Adherence Opioids Substance-Use Disorders VA

Evaluation of Changes to a Telephone Tobacco Treatment Clinic on Patient Access and Encounter Documentation Substance-Use Disorders VA

Evaluation of Clinicians’ Willingness to Prescribe Buprenorphine-based Products to Veterans with Opioid Use Disorder Opioids Substance-Use Disorders VA OUD Buprenorphine

Evaluation of Methadone Usage at a Tertiary Care Facility Education/Stigma Opioids Substance-Use Disorders Transitions Of Care

Evaluation of Pharmacist Prediabetes Education in Patients Prescribed Antipsychotics Antipsychotics Education/Stigma

Evaluation of Prescribing Rates of Selective Serotonin Reuptake Inhibitors (SSRIs) During the COVID-19 Pandemic: A Retrospective Review of United States Community Pharmacy Data Antidepressants Prescribing

Evaluation of the Efficacy of Long Acting Injectable Antipsychotics Initiated Earlier in Treatment Antipsychotics Long-Acting Injectable

Evaluation of the Impact of a Mental Health Pharmacist in a Veterans Treatment Court Team Substance-Use Disorders Transitions Of Care VA Treatment Court

Evaluation of the impact of COVID-19 on a pharmacist-led tobacco cessation clinic at Providence Veterans Affairs Healthcare System Substance-Use Disorders VA Smoking Cessation COVID-19

Evaluation of treatment outcomes among veterans with Type II Diabetes Mellitus and Severe Mental Illness taking oral vs. long-acting injectable antipsychotics Adherence Antipsychotics Long-Acting Injectable VA Diabetes

Evaluation of Virtual Academic Detailing on Naloxone Prescribing at the U.S. Veterans Health Administration Opioids Substance-Use Disorders VA Academic Detailing Naloxone

Expansion of Pharmacist-Conducted Suicide Risk Screenings in a Veterans Affairs Primary Care Clinic Education/Stigma Suicide VA Primary Care

Factors Associated with COVID-19 Vaccination for Patients in an Inpatient Forensic Psychiatric Hospital COVID-19 Vaccine Forensic

Follow-up Evaluation of Opioid Safety Initiative Patients: Focus on Early Adopter Outcomes and Suicide Opioids Suicide VA

Frequency of Stimulant Induced Mood Instability in Bipolar Disorder Antipsychotics Stimulants Mood Stabilizers

Getting de Pointes Across: Methadone and Torsades: A Case Report Opioids Substance-Use Disorders Methadone Torsades De Pointe Isoproterenol

Glutamatergic Dependence of the Ketamine-like Rapid-acting Antidepressant RO-25-6981 and Its Analogs Antidepressants Ro-25-6981 Ketamine NMDA Receptor Monoamines

Healthcare Student Perceptions of Substance Use Disorder Pre/post Elective Courses Education/Stigma Substance-Use Disorders

Home Antidepressant Prescribing During Hospitalization Antidepressants Transitions Of Care

Impact of 7-Day Medication Supply Limits on Medication Possession in Veterans Following Assignment of a High Risk Flag for Suicide Adherence Suicide VA Policy High-Risk High Risk Veteran

Impact of a Pharmacist-lead Psychopharmacology Consult Service for Veterans with Treatment-resistant Depression Antidepressants VA Consult Depression

Impact of a Pharmacist-Led Transgender Male Health Education Group on Hormone Therapy and Mental Health Disparities Among Veterans Adherence Antidepressants Antipsychotics Anxiolytics Education/Stigma Long-Acting Injectable Opioids Post-Traumatic Stress Disorder/ PTSD Sleep Disorder Stimulants Substance-Use Disorders Suicide VA Mood Stabilizers Transgender Non-Binary LGBTQIA+ Disparities Gender-Affirming Hormone Therapy

Impact of concomitant buspirone for behavioral disturbances treated with antipsychotics in a Veterans Affairs Healthcare System (VAHCS) Community Living Center (CLC) setting Antipsychotics Anxiolytics Geriatrics

Impact of Early Re-initiation of Psychotropic Medications on ICU delirium in Patients with Underlying Psychiatric Disorders Adherence Antidepressants Antipsychotics Neurology Delirium Intensive Care Unit

Impact of Long-acting Injectable Antipsychotics on Clinical Relapse and Hospitalization: A Mirror Image Study Adherence Antipsychotics Long-Acting Injectable

Impact of Participation in an Adolescent Medication Education Group on Intern Psychotropic Medication Knowledge Adherence Antidepressants Antipsychotics Anxiolytics Child And Adolescent Psychiatry Education/Stigma Stimulants Mood Stabilizers Student Pharmacist Training

Impact of Pharmacist Interventions on Psychotropic Medications Prescribed in the Geriatric Population at a Veterans Affairs Hospital Antidepressants Antipsychotics Anxiolytics Geriatrics Post-Traumatic Stress Disorder/ PTSD VA Mood Stabilizers

Impact of Pharmacist led training on nurses' knowledge and confidence in administration of second generation long-acting injectable antipsychotics (SG-LAIAs) Antipsychotics Long-Acting Injectable Education/Training Medication Administration

Impact of Pharmacist-led Benzodiazepine Taper via e-consult service Anxiolytics Geriatrics Sleep Disorder VA Benzodiazepine

Impact of Pharmacist-Led Medication Education In Reducing Use of Benzodiazepines In Veterans of High-Risk Groups Anxiolytics Geriatrics Post-Traumatic Stress Disorder/ PTSD Substance-Use Disorders VA

Impact of Social Determinant of Health on Medication Management in a Mental Health Clinic During the COVID-19 Pandemic Adherence Social Determinants Of Health Patient Outcomes COVID-19 Clinical Global Impression

Implementation of a Multi-Disciplinary Overdose Review Team Opioids Suicide VA Overdose

Implementation of a Pharmacist-Driven Mental Health COVID-19 Continuation of Care Clinic (MH-CCC) to Improve Psychiatric Symptoms in Post-Infection Patients Transitions Of Care COVID-19 Screenings Psychiatric Pharmacist Providers

Implementation of a Pharmacy Student Medication Reconciliation Program for a Psychiatric Medicine Service Education/Stigma Transitions Of Care VA Pharmacy Student Quality Improvement

Implementation of a Quality Improvement Process for Long-Acting Injectables (LAIs) at Community Based Outpatient Clinics Antipsychotics Long-Acting Injectable VA

Implementation of an Educational Pharmacy Service in an Outpatient Mental Health Clinic and its Effects on Medication Related Education Satisfaction and Overall Psychotropic Medication Adherence Adherence Antidepressants Antipsychotics Anxiolytics Education/Stigma Mood Stabilizers Medication Adherence Counseling Polypharmacy Medication Support

Implementing a Harm Reduction Kit Pilot Program for Unstably Housed Veterans Opioids Stimulants Substance-Use Disorders VA Harm Reduction Homeless Persons Illicit Drugs Pilot Projects Naloxone

Improving Access and Identifying Barriers to Pharmacologic Treatment for Bipolar Disorder Antipsychotics VA Mood Stabilizers Bipolar Disorder

Improving Documentation and Patient Education on Psychotropic Drug-Drug Interactions in an Adult Psychiatry Clinic at an Academic Medical Center Education/Stigma Interprofessionalism Drug-Drug Interactions Patient Safety

Improving Student Access to Counseling and Psychiatric Services (CAPS) Education/Stigma Mental Health

Incidence of Adverse Events Associated With Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated With Huntington’s Disease Neurology Tardive Dyskinesia VMAT2 Inhibitor Adverse Events

Increasing Access to Buprenorphine/Naloxone in the Inpatient Setting Education/Stigma Opioids Substance-Use Disorders VA

Increasing Access to Psychiatric Care During a Global Pandemic through Clinical Pharmacist Practitioner Services Access To Care Clinical Pharmacist Practitioner Global Pandemic COVID-19

Increasing the Utilization of Medication for Alcohol Use Disorder within a Veteran Population Education/Stigma Substance-Use Disorders VA

Increasing Utilization of Pharmacogenetic Testing by Mental Health Clinicians Antidepressants Pharmacogenomics

Influence Of Cannabis On Effectiveness Of Esketamine And Ketamine For Treatment Resistant Depression (TRD) Antidepressants VA

Inpatient Utilization of 21-Day Dosed Invega Sustenna® ; A Retrospective Cohort Study Antipsychotics Long-Acting Injectable

Integration of Population Management Tools into Clinical Practice to Promote Long-Acting Injectable Psychotropic Medication Safety Adherence Antipsychotics Long-Acting Injectable VA

Life Saving Collaboration: The Pharmacist Practitioner Solution in Substance Use Disorder Treatment Education/Stigma Opioids Substance-Use Disorders VA

Long-Term Efficacy and Safety of Deutetrabenazine in Patients With Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist Use Neurology Tardive Dyskinesia VMAT2 Inhibitor Dopamine Receptor Antagonist

Medication Regimen Complexity and Deprescribing in ADRD: A Review of Clinical Psychiatry Guidelines Adherence Antidepressants Antipsychotics Geriatrics Guidelines Literature Review

Medication Use Evaluation of Buprenorphine Long-acting Injectable in a Veterans Affairs Hospital Long-Acting Injectable Substance-Use Disorders VA

Mental Health Matters: Benefits of Student-led Interventions Education/Stigma Suicide

Mental Health of Students on Experiential Rotations During the COVID-19 Pandemic Education/Stigma Experiential Education COVID-19

Metabolic Monitoring and Outcomes for Patients Taking Second Generation Antipsychotics: Impact of a Quality improvement initiative over 15 Months Antipsychotics Quality Improvement Metabolic Monitoring

Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population Neurology Medical Cannabis MS/ Multiple Sclerosis

Network Meta-Analysis of Cohort Studies Involving Oral and Long-Acting Injectable Antipsychotic Agents: Administration Frequency and Incidence Rate or Odds of Hospitalization in Schizophrenia Antipsychotics Long-Acting Injectable Schizophrenia

Obtaining Prospective Patient Consent to Conduct Retrospective Data Analysis in Psychiatry Antipsychotics Informed Consent

Once-Monthly Paliperidone Palmitate Adherence during the COVID-19 Pandemic Adherence Antipsychotics

Opioid Prescription Dispensing Patterns Among Patients With Schizophrenia or Bipolar Disorder Antipsychotics OLZ/SAM Comorbidities Chronic Vs Non-Chronic

Opioid Requirements 48 Hours Post-operatively in Patients on Chronic Buprenorphine with Buprenorphine Continued vs Held Opioids Substance-Use Disorders Transitions Of Care Pain

Optimizing the Role of the Clinical Pharmacist Practitioner in Collaborative Buprenorphine Management to Improve Rural Access Opioids Substance-Use Disorders VA

Outcomes of Antipsychotic Monotherapy vs. Polypharmacy in Patients with Schizophrenia or Schizoaffective Disorder Antipsychotics VA Polypharmacy Schizophrenia Schizoaffective Disorder Medication Outcomes Prescribing Practices

Outcomes of Paliperidone Palmitate Initiation at a County Psychiatric Hospital Antipsychotics Long-Acting Injectable Transitions Of Care

Outpatient Naloxone Prescribing for Patients with Opioid Use Disorder: Improving the Quality of Providing a Life-Saving Medication Opioids Substance-Use Disorders VA

Paliperidone-Induced Sialorrhea: A Case Report with Review of Current Literature Antipsychotics Long-Acting Injectable Paliperidone Sialorrhea / Hypersalivation / Drooling Supratherapeutic

Patient and Healthcare Professional Preferences and Treatment Experiences With TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA) Risperidone Formulation Antipsychotics Long-Acting Injectable Schizophrenia

Patient Specific Factors Associated with Low Dose Induction of Buprenorphine Opioids Substance-Use Disorders

Persistence of Vesicular Monoamine Transport 2 Inhibitor Therapy for Tourette Syndrome and Chronic Tic Disorders Neurology VMAT2 Inhibitors Persistence

Pharmacist Impact on Appropriate Stimulant Prescribing in Veteran Outpatients Stimulants VA

Pharmacist Involvement in Medication Reconciliation at a Forensic Psychiatric Hospital Medication Reconciliation

Pharmacist-led Identification of Behavioral Health Transitions of Care Errors and Prevention Initiatives Within a Large Health System Adherence Antipsychotics Long-Acting Injectable Suicide Transitions Of Care Mood Stabilizers Psychotropics

Pharmacokinetic Drug Interactions with Oral Haloperidol: Dose Correction Factors from a Combined Weighted Analysis Antipsychotics Haloperidol Pharmacokinetics Drug-Drug Interactions Cytochrome P-450

Pharmacy Directed Linkage to Mental Health Resources After Anxiety Screening Transitions Of Care Community Pharmacy Anxiety Linkage To Care

Pharmacy Driven Medication Reconciliation for Pediatric Patients with Mental Health Conditions in the Emergency Department: A Pilot Study Child And Adolescent Psychiatry Transitions Of Care Medication Reconciliation

Pharmacy-Driven Intervention for the Appropriate Use of Droperidol in Acute Agitation Management Antipsychotics Acute Agitation Droperidol

Phenobarbital Requirements for Patients Using Synthetic Benzodiazepines Anxiolytics Substance-Use Disorders

Practical Approaches to Antidepressant-Associated QTc Prolongation: A Review of Cases. Antidepressants QTc Prolongation

Prescribing Trends of Psychiatric Medications Within an Adult Burn Center Antidepressants Antipsychotics Anxiolytics Education/Stigma Post-Traumatic Stress Disorder/ PTSD Sleep Disorder Substance-Use Disorders Transitions Of Care

Prevalence of Actionable Pharmacogenomic Phenotypes in Veterans with Major Depressive Disorder (MDD) Receiving Antidepressants Adherence Antidepressants Pharmacogenomics VA

Prevalence of Impostor Phenomenon Among Graduate Students in Pharmacy and Counseling Psychology Education/Stigma Impostor Phenomenon

Prevalence of Psychotropic Drug Use in Children Aged 6-17: NHANES 2013-2018 Antidepressants Antipsychotics Anxiolytics Child And Adolescent Psychiatry Stimulants

Process and Outcomes for Ambulatory Child/Adolescent Clinical Psychiatric Pharmacy Service Expansion within an Academic Medical Center Child And Adolescent Psychiatry Transitions Of Care

Prospective Analysis of the Effect of Pharmacist-Led Medication Groups on Patient Outcomes Adherence Education/Stigma Transitions Of Care

Protocol Development for Initiation of Buprenorphine Products in the Emergency Department for Opioid Use Disorder Opioids Substance-Use Disorders VA

Psychedelic-assisted Psychotherapy in the Treatment of Anxiety and Trauma-related Disorders Anxiolytics Post-Traumatic Stress Disorder/ PTSD Psychedelics Psychotherapy Anxiety Trauma-Related Disorders

Psychiatric Pharmacist Impact on Antipsychotic Polypharmacy Usage and Rehospitalization Rates in a Safety-Net Inpatient Psychiatric Hospital Antipsychotics Long-Acting Injectable Polypharmacy

Raising Awareness About Substance Use Disorder and Expanding Understanding of Opioid Overdose Through Naloxone Administration and Harm Reduction Training In Undergraduate Student Education/Stigma Opioids Substance-Use Disorders Naloxone Harm Reduction

Real-world Evaluation of Treatment Patterns Following Initiation of Medication for Alcohol Use Disorder (MAUD) among Veterans Adherence Long-Acting Injectable Substance-Use Disorders VA

Recognizing the Role of Socioeconomic Geography in the Distribution of Waivered Providers Opioids Social Determinants Of Health

Retrospective Evaluation of Ketamine for the Management of Acute Agitation in the Emergency Department Ketamine Acute Agitation Emergency Department

Risk Factors Associated with Treatment Failure with SSRI Monotherapy in College Students with MDD Antidepressants College Students SSRI

Rural Access to Mental Health Clinical Pharmacy Services VA Access To Mental Health Pharmacists

Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia: A Long-term, Multicenter, Open-label Study Antipsychotics Schizophrenia Adolescent Brexpiprazole Interim Analysis Long-Term Safety & Efficacy

Safety of Sedating Antidepressants Compared to Benzodiazepine Receptor Agonists for the Treatment of Insomnia in Patients Diagnosed with Bipolar Disorder: A Retrospective Review Antidepressants Sleep Disorder VA Bipolar Disorder

Serdexmethylphenidate/d-Methylphenidate (SDX/d-MPH) Capsules For Children With ADHD: Effects On SKAMP-C Evaluated Over 13 Hours In A Randomized, Double-Blind, Placebo-Controlled Laboratory Classroom Study Child And Adolescent Psychiatry Neurology Stimulants Dexmethylphenidate ADHD Serdexmethylphenidate

Somnambulism Associated with Lithium Monotherapy Sleep Disorder Mood Stabilizers Medication Safety

Stimulant Prescribing Trends Following Implementation of Controlled Substance Ordering Restrictions at a Veterans Affairs Health Care System Stimulants VA ADHD

Successful Clozapine Rechallenge after Suspected Clozapine-Induced Myocarditis: A Case Report Antipsychotics Suicide Rechallenge Medication Side Effect Clozapine

Successful Electroconvulsive Therapy After Failed Pharmacotherapies in an Older Female on Hemodialysis with Bipolar Mania Antipsychotics Mood Stabilizers Therapeutic Drug Monitoring Dialysis Bipolar Disorder Electroconvulsive Therapy

Testing of the Submission Platform Anxiolytics Stimulants Mood Stabilizers Practice Custom

The Impact of a Clinical Reminder Order Check and Provider Education on Anticholinergic Prescribing in Older Adults Geriatrics VA Anticholinergic Deprescribing

The Intersection of Race, Mental Illness, and COVID-19: Reducing Barriers to COVID-19 Vaccine Uptake through a Pharmacy Driven Culturally Sensitive Patient Medication Education Group (PMEG) Education/Stigma COVID-19 Vaccine Health Disparities Race

The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Bipolar Depression: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials Antipsychotics Bipolar Disorder Lumateperone

The Use of The Pharmacists’ Inventory for Learning Styles (PILS) to Improve Student Learning Outcomes on a Psychiatric Pharmacy Rotation Experience Education/Stigma Learning Assessment

Therapeutic Drug Monitoring of Psychiatric Medications at a Bariatric Surgery Medication Management Service Antidepressants Antipsychotics Mood Stabilizers Therapeutic Drug Monitoring Bariatric Surgery

Trends in Antipsychotic Prescribing for Approved and Unapproved Indications to Medicaid-enrolled Youth in Philadelphia, Pennsylvania between 2014 and 2018 Antipsychotics Child And Adolescent Psychiatry Medicaid Population

Trends of Discharge Disposition in Re-Hospitalized Patients Prescribed Long-Acting Injectable Antipsychotics Adherence Antipsychotics Long-Acting Injectable

Understanding Pharmacy-Related Barriers to Care in Medication-Assisted Treatment Therapy: Perspectives from Peer Recovery Coaches Education/Stigma Opioids Substance-Use Disorders Peer Recovery Coaches Community Pharmacy

Utilization Of Droperidol Versus Haloperidol For Acute Agitation In Psychiatric Patients Within The Emergency Department Antipsychotics Acute Agitation Droperidol Haloperidol

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype-to-Phenotype Interpretations Education/Stigma Pharmacogenomics

Weight and Metabolic Outcomes in Patients with Schizophrenia Receiving up to 25- or 52-Week Treatment With Aripiprazole Lauroxil Antipsychotics Long-Acting Injectable Weight-Gain Metabolic Syndrome Safety Aripiprazole Lauroxil

Zuranolone in Major Depressive Disorder: Results From the Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled WATERFALL Study Antidepressants Major Depression Neuroactive Steroid GABA Signaling

‘Can we Order a Lipid Profile?’ A Pharmacist-Led Metabolic Monitoring Protocol for Patients Prescribed Antipsychotics in an Inpatient Psychiatric Hospital Antipsychotics Metabolic Monitoring Cardiovascular Diseases/arrhythmias Diabetes